摘要
目的 探讨白细胞介素-23在转移性前列腺癌患者中的检测价值。方法 选取2017年1月至2021年1月间宝山区罗店医院接受治疗的74例转移性前列腺癌患者为观察组,选取同期入院治疗的94例非转移性前列腺癌患者和62例前列腺增生患者分别为对照A组和对照B组。比较三组患者血清白细胞介素-23水平,比较168例前列腺癌患者不同病理分期下血清白细胞介素-23水平,建立COX风险比例回归模型,研究血清白细胞介素-23与转移性前列腺癌进展的关系。结果 观察组患者血清白细胞介素-23水平为(26.37±1.23)μg/L,对照A组患者为(18.28±2.33)μg/L,对照B组患者为(9.87±1.50)μg/L,观察组、对照A组、对照B组的白细胞介素-23依次减少,差异均有统计学意义(均P<0.05)。不同病理分期前列腺癌患者血清白细胞介素-23比较显示,T1~T2期患者血清白细胞介素-23水平为(16.87±2.38μ)g/L,T3期为(24.86±2.15)μg/L,T4期为(28.17±2.34)μg/L,白细胞介素-23水平随着分期增加而增加,差异均有统计学意义(均P<0.05)。COX风险比例回归模型显示,血清白细胞介素-23水平与前列腺癌进展程度有明显相关性,白细胞介素-23水平越高,前列腺癌进展程度越高,差异有统计学意义(P<0.05)。结论 白细胞介素-23水平与转移性前列腺癌病情进展有明显相关性,病理分期越高,血清白细胞介素-23水平越高,可作为预测转移性前列腺癌进展程度的有效指标。
Objective To explore the expression level and detection value of interleukin-23 in patients with metastatic prostate cancer. Methods Seventy-four patients with metastatic prostate cancer who received treatment at Luodian Hospital, Shanghai Baoshan District were selected from January 2017 to January 2021 and were enrolled in an observation group. Ninety-four patients with non-metastatic prostate cancer and 62 patients with prostate hyperplasia who were hospitalized during the same period were selected and enrolled in control group A and control group B, respectively. The level of serum interleukin-23 was compared in three groups. The levels of serum interleukin-23 were also compared in 168 prostate cancer patients of different pathological stages. Cox risk proportional regression model was established to study the relationship between serum interleukin-23 and the progression of metastatic prostate cancer. Results The serum level of interleukin-23 was 26.37±1.23 μg/L in the observation group followed by 18.28±2.33 μg/L in control group A and 9.87±1.50 μg/L in control group B(all P<0.05). Comparison of serum interleukin-23 in prostate cancer patients with different pathological stages showed that the serum interleukin-23 level was 16.87±2.38 μg/L in T1 to T2 group, 24.86±2.15 μg/L in T3 group and 28.17±2.34 μg/L in T4 revealing serum interleukin-23 decreased with the elevated tumor stage(P<0.05). Cox risk proportional regression model showed that the level of serum interleukin-23 was significantly associated with the progression of prostate cancer, and the higher the level of interleukin-23 was, the higher the progression of prostate cancer was. Conclusion The level of interleukin-23 is significantly associated with the progression of metastatic prostate cancer. The high the level of serum interleukin-23 is associated with the high pathological stage. The level of interleukin-23 can be used as an effective indicator to predict the progression of metastatic prostate cancer.
作者
陈晓艳
李虎
严春霞
沈冬明
CHEN Xiao-yan;LI Hu;YAN Chun-xia;SHEN Dong-ming(Clinical Laboratory,Luodian Hospital,Baoshan District,Shanghai 201908,China)
出处
《中国肿瘤临床与康复》
2022年第7期839-842,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
